Tumor Evolution: Finding the mutations that drive resistance

Mutations that allow tumors to evolve and become resistant to treatment can be readily identified with a new sequencing approach.
  1. Nadine Bley  Is a corresponding author
  1. Department of Molecular Cell Biology, Martin Luther University Halle-Wittenberg, Germany
  2. Institute of Molecular Medicine, Martin Luther University Halle-Wittenberg, Germany

Despite being a major cause of death, cancer is still far from being fully understood. Most cancer treatments target mutations that happen during the very early stages of the disease, as these genetic variants will be present in the majority of tumor cells (Bailey et al., 2018). However, not all cells inside a tumor are genetically identical, and this heterogeneity is one of the biggest problems in cancer therapy (Gatenby and Brown, 2018). As tumors evolve and become more heterogeneous, some cancer cells acquire new mutations that make them resistant to certain treatments, and drugs targeting these sites could prevent cancers from reoccurring (Figure 1A).

Detecting rare mutations in tumor cells.

(A) Cancer usually begins with a mutation (dark blue shape in top cell) in a single tumor cell that it passes on to its daughter cells following division. A daughter cell can then gain a new mutation (shown in pink) that it passes on to its progeny. These cells also divide and acquire new mutations (shown in different colors). Over time this leads to a population of cells that are genetically distinct from each other: the initial mutation is present in all the cells, whereas mutations that occurred later are present in a smaller number of cells (bottom row). (B) Now, KaramiNejadRanjba et al. have created a sequencing approach called DigiPico that can identify mutations that occur later during tumor evolution. First, cell material is extracted from a small group of 20–30 cells using laser microdissection and diluted down to single molecules of DNA which are plated into 384 individual wells (top panel). The DNA molecule in each well is amplified to create individual libraries, which are then combined and sequenced (bottom panel). After sequencing, an artificial neural network called MutLX is applied to the data to determine which of the genetic variants put into the algorithm (shown in dark red) are mutations that appear later during tumor evolution (shown in dark blue) and which are artefacts generated by the amplification process. Figure created using BioRender (BioRender.com).

Whole-genome sequencing is a widely used strategy for identifying genetic variants which are present in the majority of tumor cells. However, mutations that arise later during tumor evolution are almost impossible to detect using this approach, as they only appear in a handful of cells (Figure 1A; Hrdlickova et al., 2017; Turajlic et al., 2019). Although whole-genome sequencing of single cells can uncover these rarer mutations, this technique requires a high number of individual cells, which are often difficult to collect and expensive to sequence. In addition, amplifying the small quantities of DNA extracted from tumor cells often introduces errors that can be mistaken for cancer mutations. Now, in eLife, Ahmed Ahmed from the University of Oxford and co-workers from the United Kingdom and Germany – including Eli M Carrami as first author – report how they developed a new whole-genome sequencing technique that can overcome these limitations and identify mutations that occur later in tumor evolution (Carrami et al., 2020).

In the first stage of this approach, termed DigiPico, genomic material was extracted from a small group of tumor cells and diluted down to 384 single molecules of DNA (Figure 1B). Each DNA molecule was then individually amplified to create a library of repeated fragments which were sequenced into reads. Carrami et al. hypothesized that if a mutation is randomly generated during the amplification process, it will only appear in a small proportion of the repeated fragments. However, if a mutation is truly related to the cancer sample, it will be present from the start and will therefore be detected in all the reads that result from amplifying the single DNA molecule. Moreover, true mutations that arise during tumor evolution will be distributed regularly across the different libraries, while artefacts that arise during amplification will appear more randomly.

The sequencing data were analyzed using common processing and mapping algorithms and compared to whole-genome sequencing data from the tumor material and blood of the same patient. This identified genomic variants that were unique to the DigiPico data, and true positive mutations that were also found in the majority of tumor cells and the blood of patients. KaramNejadRanjbar et al. then employed a neural network called MutLX, which uses a form of artificial intelligence, to determine whether the unique variants detected by DigiPico were artefacts or cancer related mutations (LeCun et al., 2015). Excluding artefacts dramatically decreased the number of candidates for mutations that occurred late in the evolution of the tumor.

Experimentally validating some of the detected mutants revealed that together, DigiPico and MutlX, are able to eliminate false positives and identify rare mutations. Using the new technique, KaramNejadRanjbar et al. were able to discover a hyper-mutation event called kataegis in a recurring ovarian tumor (Chan and Gordenin, 2015), which conventional sequencing approaches had not been able to detect.

One of the main advantages of this method is that it can identify rare mutations that appear late during tumor evolution from just a small sample of cells. Furthermore, the precision and robustness of the technique also makes it easier to characterize current mutational processes, even in cancers which have a high number of genomic re-arrangements, such as ovarian tumor cells. These findings demonstrate how DigiPico and MutLX can be used to study the evolution of tumors, during cancer development, progression and recurrence.

References

Article and author information

Author details

  1. Nadine Bley

    Nadine Bley is in the Department of Molecular Cell Biology and the Institute of Molecular Medicine, Martin Luther University Halle-Wittenberg, Halle, Germany

    For correspondence
    nadine.stoehr@medizin.uni-halle.de
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4531-7998

Publication history

  1. Version of Record published: May 15, 2020 (version 1)

Copyright

© 2020, Bley

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,318
    Page views
  • 117
    Downloads
  • 1
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Nadine Bley
(2020)
Tumor Evolution: Finding the mutations that drive resistance
eLife 9:e57678.
https://doi.org/10.7554/eLife.57678

Further reading

    1. Cancer Biology
    2. Chromosomes and Gene Expression
    Justin H Hwang et al.
    Research Article Updated

    Metastatic castration-resistant prostate cancers (mCRPCs) are treated with therapies that antagonize the androgen receptor (AR). Nearly all patients develop resistance to AR-targeted therapies (ARTs). Our previous work identified CREB5 as an upregulated target gene in human mCRPC that promoted resistance to all clinically approved ART. The mechanisms by which CREB5 promotes progression of mCRPC or other cancers remains elusive. Integrating ChIP-seq and rapid immunoprecipitation and mass spectroscopy of endogenous proteins, we report that cells overexpressing CREB5 demonstrate extensive reprogramming of nuclear protein–protein interactions in response to the ART agent enzalutamide. Specifically, CREB5 physically interacts with AR, the pioneering actor FOXA1, and other known co-factors of AR and FOXA1 at transcription regulatory elements recently found to be active in mCRPC patients. We identified a subset of CREB5/FOXA1 co-interacting nuclear factors that have critical functions for AR transcription (GRHL2, HOXB13) while others (TBX3, NFIC) regulated cell viability and ART resistance and were amplified or overexpressed in mCRPC. Upon examining the nuclear protein interactions and the impact of CREB5 expression on the mCRPC patient transcriptome, we found that CREB5 was associated with Wnt signaling and epithelial to mesenchymal transitions, implicating these pathways in CREB5/FOXA1-mediated ART resistance. Overall, these observations define the molecular interactions among CREB5, FOXA1, and pathways that promote ART resistance.

    1. Cancer Biology
    2. Computational and Systems Biology
    Gökçe Senger et al.
    Research Article Updated

    Aneuploidy, a state of chromosome imbalance, is a hallmark of human tumors, but its role in cancer still remains to be fully elucidated. To understand the consequences of whole-chromosome-level aneuploidies on the proteome, we integrated aneuploidy, transcriptomic, and proteomic data from hundreds of The Cancer Genome Atlas/Clinical Proteomic Tumor Analysis Consortium tumor samples. We found a surprisingly large number of expression changes happened on other, non-aneuploid chromosomes. Moreover, we identified an association between those changes and co-complex members of proteins from aneuploid chromosomes. This co-abundance association is tightly regulated for aggregation-prone aneuploid proteins and those involved in a smaller number of complexes. On the other hand, we observed that complexes of the cellular core machinery are under functional selection to maintain their stoichiometric balance in aneuploid tumors. Ultimately, we provide evidence that those compensatory and functional maintenance mechanisms are established through post-translational control, and that the degree of success of a tumor to deal with aneuploidy-induced stoichiometric imbalance impacts the activation of cellular protein degradation programs and patient survival.